MSD Korea Holds Event to Mark 10 Years of Keytruda Lung Cancer Approval, Third-Quarter Results Also Rise Sharply
Published
MSD Korea held an event to celebrate the 10th anniversary of the approval of Keytruda (Keytruda), an immuno-oncology drug, for lung cancer treatment in Korea. Keytruda is a treatment that helps prevent cancer cells from avoiding attacks by immune cells, and it is used to treat lung cancer patients in Korea.
The event was organised to look back on how Keytruda has been used to treat lung cancer in Korea over the past ten years. Company representatives attended and shared the achievements so far.
Meanwhile, the company's business results also improved. Cumulative sales revenue up to the third quarter of this year was 260.3 billion won, operating profit was 152.4 billion won, and net profit was 143.5 billion won. These figures are increases of 72.0%, 74.6% and 102.8%, respectively, compared with the same period last year.
This 10th anniversary event and the results announcement show that Keytruda has been used for a long time in the field of lung cancer treatment in Korea. Attention is also growing on what plans the company is making for the future.
Sources: 더바이오
More South Korea news
- US Air Taxi Company Joby Posts Higher Third-Quarter Revenue on Growth of Subsidiary's Passenger Business
- CJ Olive Young Aims to Become a "Global Tech Platform" Led by AI
- Smart farming company GreenFarm to enter domestic and overseas markets in partnership with Korea Agricultural Development Institute
- Alchera's Subsidiary YouSeeB to Take Part in Korea Fintech Week 2026
- How Will China's Manufacturing Growth Affect South Korea's Future?
- South Korea Ranks First in UN E-Government Survey for the First Time in 12 Years
- President Lee's approval rating at 40%; Democratic Party 36%, People Power Party 28%, ruling party leads
- Presidential Secretary Im Kwang-hyun Visits the National Council of Churches in Korea, Continuing Dialogue with Religious Groups